- Garenoxacin
-
- $1000.00
-
2019-07-06
- CAS:223652-90-2
- Min. Order: 25KG
- Purity: 99%
- Supply Ability: 10tons
|
| | Garenoxacin Basic information |
| Product Name: | Garenoxacin | | Synonyms: | 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid methanesulfonate hydrate;Garenoxacin mesylate hydrate;Garenoxacin mesylate hydrate
1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid methanesulfonate hydrate;(R)-1-cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound with methanesulfonic acid (1:1) hydrate;1-cyclopropyl-8-(difluoromethoxy)-4-keto-7-[(1R)-1-methylisoindolin-5-yl]quinoline-3-carboxylic acid;BMS284756 (Mesylate hydrate);Garenoxacin mesylate [USAN];Garenoxacin mesylate monohydrate >=98% (HPLC) | | CAS: | 223652-90-2 | | MF: | C23H20F2N2O4.CH4O3S.H2O | | MW: | 540.53 | | EINECS: | | | Product Categories: | | | Mol File: | 223652-90-2.mol |  |
| | Garenoxacin Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMSO:100.0(Max Conc. mg/mL);185.0(Max Conc. mM)
Water:12.5(Max Conc. mg/mL);23.13(Max Conc. mM) | | form | powder | | color | white to beige | | Water Solubility | H2O: 10mg/mL, clear (warmed) | | InChIKey | IGTHEWGRXUAFKF-NVJADKKVSA-N | | SMILES | OC(C1=CN(C2CC2)C3=C(OC(F)F)C(C4=CC(CN[C@@H]5C)=C5C=C4)=CC=C3C1=O)=O.CS(=O)(O)=O.[H]O[H] |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Garenoxacin Usage And Synthesis |
| Uses | Antibacterial agent. | | Biological Activity | Garenoxacin is a broad spectrum fluoroquinolone antibiotic suitable for treatment of gram-positive and gram-negative bacterial infections. Garenoxacin has a low mutant prevention concentration and a narrow mutant selection window. Data shows th at garenoxacin has anti-inflammatory properties. It significantly alleviates LPS-induced IL-8 production through the negative regulation of the ERK1/2 pathway both in the human airway epithelial cell line A549 and the monocyte cell line THP-1. | | in vivo | Garenoxacin (12.5-50 mg/kg; s.c.; once) is highly effective against the wild-type strain and mutants harboring a single mutation in a mouse pneumonia model with S. pneumoniainfection[4].
Garenoxacin (10 and 30 mg/kg; p.o.; once) reduces the viable cell counts in the lungs and significantly prolongs survival on experimental secondary pneumococcal pneumonia caused by S. pneumoniae D-979 in BALB/c female mice[5]. | Animal Model: | Swiss mice with S. pneumonia infection[4]. | | Dosage: | 12.5, 25 and 50 mg/kg | | Administration: | Subcutaneous injection, once | | Result: | Significantly improved the survival rate. |
| | IC 50 | Quinolone; Gyrase: 1.25 μg/mL (IC50); TOPO IV: 1.5-2.5 μg/mL (IC50) |
| | Garenoxacin Preparation Products And Raw materials |
|